I think it is pharma companies getting ahead of the curve, as regulatory approvals are slowly moving towards measuring the impact on cognition for all experimental drugs/therapies and not just ones focused on brain activity. In Europe all trials for children are required to now have cognitive assessment, and as we learn more about brain activity and development it wouldn't surprise me for that to expand to adults in the future as well.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.015(0.84%) |
Mkt cap ! $304.7M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.84 | $1.78 | $252.4K | 138.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2792 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 6891 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |